A Study of BGM-2121 in Patients With Advanced Solid Tumors
NCT ID: NCT07346846
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
35 participants
INTERVENTIONAL
2026-02-28
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of MG2512 Injection in Participants With Advanced Solid Tumors
NCT07348653
A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors
NCT07077434
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06475131
GenSci143 in Participants With Advanced Solid Tumors
NCT07252414
EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
NCT05341492
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BGM-2121
BGM-2121
BGM-2121 treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BGM-2121
BGM-2121 treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Has a confirmed diagnosis of advanced solid tumor(s),
3. The subject has received and failed standard-of-care anti-cancer therapy
4. Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)
5. ...
Exclusion Criteria
2. Has signs or symptoms of end-stage organ failure, major chronic illnesses other than cancer(s)
3. History of another primary malignancy within the last three years
4. ...
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioGate Precision Medicine Corp.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Taiwan University Hospital, Taipei Veterans General Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BGM-2121-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.